• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Vaccine. Heterosubtypic protection conferred by combined vaccination with M2e peptide and split influenza vaccine.

Giuseppe

Emeritus
Vaccine. 2008 Dec 1. [Epub ahead of print]

Heterosubtypic protection conferred by combined vaccination with M2e peptide and split influenza vaccine.

Wu F, Yuan XY, Huang WS, Chen YH. - Laboratory of Immunology, Department of Biology, Tsinghua University; Beijing Key Laboratory for Protein Therapeutics, Beijing 100084, PR China.

There is urgent need to develop influenza vaccines with broad-spectrum protection against the potential influenza pandemic.

The extracellular domain of influenza M2 protein (M2e) is considered as an appropriate target to induce heterosubtypic protection.

We investigated the immunity and protection induced by combined vaccination with synthetic M2e peptide and traditional split influenza vaccine.

The combined vaccination was able to induce similar strain-specific hemagglutinin inhibition (HI) antibodies as vaccination of split virus alone.

However, aluminum-adjuvant but not MF59-adjuvant combined vaccination was able to induce high titers of anti-M2e antibodies and provoke M2e-specific T lymphocyte response.

Furthermore, we found that the addition of M2e peptide greatly enhanced the cross-protective efficacy of split virus in aluminum adjuvant but slightly weakened the efficacy of vaccination in MF59 adjuvant.

Moreover, aluminum-adjuvant combined vaccination conferred complete cross-protection against heterosubtypic influenza virus.

According to the results, we suggest that the M2e peptide should be added into split influenza vaccine in the preparation for the potential influenza pandemic.

PMID: 19056447 [PubMed - as supplied by publisher]
-
-----
 
Back
Top